Rapid Readouts

onclive rapid readouts logo

OncLive presents Rapid Readouts. In each video, leading experts in their field present slides and posters from annual oncology conferences, symposiums, and meetings, highlighting the everchanging landscape of treatment choices for patient management.

Select Conference:
World Conference on Lung Cancer
ASCO
ASH
ESMO
AACR
SABCS
World GI
Select Year:
2021
2025
2024
2023
2022
2020

Phase 1/2 Study of Mobocertinib in mNSCLC With EGFR Exon 20 Insertions: EXCLAIM and Platinum-Pretreated Patients Cohorts

February 19th, 2021

Rapid Readouts: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naïve Chronic Lymphocytic Leukemia: ELEVATE-TN 4-Year Follow-up

July 8th, 2021

MonarchE: Primary Overall Survival Results Of Adjuvant Abemaciclib Plus Endocrine Therapy For HR+, HER2-, High-Risk Early Breast Cancer

November 25th, 2025

Final Analysis of Lenvatinib + Pembrolizumab vs Sunitinib in Patients With Advanced Renal Cell Carcinoma With or Without Bone Metastases in CLEAR

November 24th, 2025

Darovasertib Plus Crizotinib in First-Line Metastatic Uveal Melanoma: Phase 1/2 OptimUM-01 Results

November 21st, 2025

Lenvatinib Plus Pembrolizumab in Advanced Endometrial Cancer: Five-Year and Post-(Neo)Adjuvant Outcomes From KEYNOTE-775 and LEAP-001

November 21st, 2025

First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase 3 TROPION-Breast02 trial

November 14th, 2025

Intracranial activity of ifinatamab deruxtecan (I-DXd) in patients with extensive-stage small cell lung cancer and baseline brain metastases: Primary analysis of IDeate-Lung01

November 12th, 2025

Updated Results from the EDGE-Gastric Arm A1 Study

November 11th, 2025

Patient Perspectives From the Phase 3 IRAKLIA Study of Isatuximab (Isa) Subcutaneous (SC) via On-Body Injector (OBI) vs Isa Intravenous (IV) in Relapsed/Refractory Multiple Myeloma (RRMM)

November 11th, 2025

Rezatapopt For Locally Advanced or Metastatic Solid Tumors With a TP53 Y220C Mutation: Initial Analysis of the Pivotal PYNNACLE Phase 2 Trial

November 10th, 2025

Patient-Reported Outcomes From the SERENA-6 Trial of Camizestrant + CDK4/6 Inhibitor For Emergent ESR1m During First-Line Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2– Advanced Breast Cancer

November 7th, 2025

Primary Results from ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan vs Chemotherapy in Patients with Previously Untreated Advanced Triple-Negative Breast Cancer Who Are Unable to Receive PD-(L)1 Inhibitors

November 3rd, 2025

LBA1 - Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer (BC) with residual invasive disease after neoadjuvant therapy (tx): Interim analysis of DESTINY-Breast05

October 30th, 2025

Updated overall survival analysis from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC)

October 30th, 2025

DESTINY-Breast11: Neoadjuvant Trastuzumab Deruxtecan Alone (T-DXd) or Followed by Paclitaxel + Trastuzumab + Pertuzumab (T-DXd-THP) vs SOC For High-Risk HER2+ Early Breast Cancer (eBC)

October 28th, 2025

FLAURA2: Exploratory Overall Survival (OS) Analysis in Patients (Pts) with Poorer Prognostic Factors Treated with Osimertinib (Osi) ± Platinum-Pemetrexed Chemotherapy (CTx) as First-Line (1L) Treatment (Tx) for EGFR-Mutated (EGFRm) Advanced NSCLC

October 27th, 2025

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

October 23rd, 2025

Isatuximab Subcutaneous (ISA SC) via On-Body Injector (OBI) or Manual Injection For Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience From the Phase 2 IZALCO Study

October 22nd, 2025

Radiation Segmentectomy or Ablative External​ Beam Radiation Therapy as Initial Treatment for​ Solitary Hepatocellular Carcinoma: ​ A Multicenter Experience​

October 17th, 2025

Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pretreated Patients With Advanced/Metastatic ROS1+ NSCLC

October 9th, 2025

Factors associated with clinical outcomes in patients with HER2-mutant NSCLC treated with sevabertinib (BAY 2927088)

September 30th, 2025

Number Needed to Treat Analysis of Zanubrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia

September 30th, 2025

Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results from Phase 3 EMPOWER-Lung 3 Part 2 Trial

September 29th, 2025

First-Line Tagraxofusp in BPDCN: Subgroup Analyses by Age and Fitness

September 19th, 2025

Intracranial Efficacy of Datopotamab Deruxtecan (DatoDXd) in Patients With Advanced/Metastatic NSCLC in TROPION-Lung01

September 19th, 2025

Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer: Primary Analysis of the Phase 2 Ideate-Lung01 Study

September 19th, 2025

First-line Osimertinib chemo vs osimertinib mono in EGFRm Advanced NSCLC: Flaura2 final overall survival

September 18th, 2025

Elacestrant Combinations in ER+/HER2- Locally Advanced or Metastatic Breast Cancer: Efficacy and Safety Updates from the Phase 1b/2 ELEVATE Study

September 10th, 2025

Favorable Benefit-Risk Profile of Avapritinib in Indolent Systemic Mastocytosis Is Maintained After 3 Years of Therapy: Longer-Term Analysis of the PIONEER Study

July 30th, 2025

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Newly Diagnosed Multiple Myeloma (NDMM): Outcomes in Patients with 1q21⁺ Status in the Phase 3 IMROZ Study

July 15th, 2025

Lurbinectedin + Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: Primary Results of the Phase 3 IMforte Trial

July 11th, 2025

Updated Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Degrader BGB-16673 in Patients (Pts) With Relapsed or Refractory (R/R) CLL/SLL: Results From the Ongoing Phase (Ph) 1 CaDAnCe-101 Study

June 30th, 2025

Can CAR T-Cell Therapy Be a Definitive Treatment for Adult R/R B-ALL Without Transplant? Long-Term Findings and Predictors of Sustained Remission for Obecabtagene Autoleucel

June 30th, 2025

Comparative Efficacy of Zanubrutinib vs Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

June 30th, 2025

Sacituzumab Govitecan Plus Pembrolizumab vs Chemotherapy Plus Pembrolizumab in Patients With Previously Untreated, PD-L1 Positive, Advanced or Metastatic Triple-Negative Breast Cancer: Primary Results From the Randomized, Phase 3 ASCENT-04/KEYNOTE-D19 Study

June 30th, 2025

Updated Results From the Phase 1 Study of Sonrotoclax (BGB-11417), a Novel BCL2 Inhibitor, in Combination With Zanubrutinib for Relapsed/Refractory CLL/SLL, Demonstrate Deep and Durable Responses

June 27th, 2025

APPULSE-PNH: Oral Iptacopan Monotherapy Demonstrates Clinically Meaningful Hemoglobin (Hb) Increases in Patients (Pts) With Paroxysmal Nocturnal Hemoglobinuria (Pnh) and Hb ≥10 G/Dl Oo Anti-C5 Therapy

June 26th, 2025

Combination Treatment With Novel BCL2 Inhibitor Sonrotoclax (BGB-11417) and Zanubrutinib Induces High Rate of Complete Remission for Patients With Relapsed/Refractory Mantle Cell Lymphoma

June 26th, 2025

Petosemtamab (MCLA-158) With Pembrolizumab as First-Line (1L) Treatment of PD-L1+ Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 2 Trial

June 25th, 2025

A First-in-Human, Phase 1a/b, Dose-Escalation/Expansion Study of BG-68501, a Selective CDK2 Inhibitor, as Monotherapy or in Combination With Fulvestrant for Patients With HR+/HER2– Breast Cancer and Other Advanced Solid Tumors: First Disclosure of Clinical Data

June 24th, 2025

ARCHES: 5-Year Follow-up Overall Survival (OS) Analysis of Enzalutamide (ENZA) Plus Androgen-Deprivation Therapy (ADT) in Patients (pts) With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

June 24th, 2025

Event-free Survival (EFS) in MATTERHORN: A Randomized, Phase 3 Study of Durvalumab plus 5-Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel Chemotherapy (FLOT) in Resectable Gastric/Gastroesophageal Junction Cancer (GC/GEJC)

June 23rd, 2025

First-in-human study of BG-C9074, a B7-H4-targeting ADC in patients with advanced solid tumors: Preliminary results of the dose-escalation phase

June 23rd, 2025

DAREONTM-9, a Phase 1b Study of Obrixtamig Plus Topotecan in Patients (Pts) With Advanced Small Cell Lung Cancer (SCLC): Interim Analysis Results

June 23rd, 2025

Isatuximab (Isa) subcutaneous (SC) via an on-body delivery system (OBDS) vs Isa intravenous (IV), plus pomalidomide and dexamethasone (Pd) in relapsed/refractory multiple myeloma (RRMM): Results of the randomized, non-inferiority, Phase 3 IRAKLIA study

June 20th, 2025

ROSELLA: A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Patients With Platinum-Resistant Ovarian Cancer (GOG-3073, ENGOT-ov72)

June 20th, 2025

Efficacy and Safety of the DLL3/CD3 T-Cell Engager Obrixtamig in Patients With Extrapulmonary Neuroendocrine Carcinomas With High or Low DLL3 Expression: Results From an Ongoing Phase 1 Trial

June 20th, 2025

Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia (R/R CLL): A Matching-Adjusted Indirect Comparison (MAIC)

June 19th, 2025

An All-Oral Regimen of Decitabine-Cedazuridine (DEC-C) Plus Venetoclax (VEN) in Patients With Newly Diagnosed AML Ineligible for Intensive Induction Chemotherapy: Results From a Phase 2 Cohort of 101 Patients

June 19th, 2025

Updated Efficacy of Mutant-Selective PI3Kα Inhibitor RLY-2608 in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial

June 18th, 2025

Trastuzumab Deruxtecan (T-DXd) + Pertuzumab (P) vs Taxane + Trastuzumab + Pertuzumab (THP) for First-Line (1L) Treatment of Patients With Human Epidermal Growth Factor Receptor 2–Positive (HER2+) Advanced/Metastatic Breast Cancer (a/mBC): Interim Results From DESTINY-Breast09

June 17th, 2025

Combination of Zanubrutinib (Zanu) + Venetoclax (Ven) for Treatment-Naive (TN) CLL/SLL: Results in SEQUOIA Arm D

June 12th, 2025

Tirabrutinib for the Treatment of Relapsed or Refractory Primary Central Nervous System Lymphoma: Efficacy and Safety From the Phase II PROSPECT Study

June 12th, 2025

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in High-Risk Relapsed/Refractory CLL: A Network Meta-Analysis

June 10th, 2025

SEQUOIA 5-year Follow-up in Arm C: Frontline Zanubrutinib Monotherapy in Patients with del(17p) and Treatment-naive CLL/SLL

June 10th, 2025

Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC

June 3rd, 2025

Preliminary Safety and Antitumor Activity of Zoldonrasib (RMC-9805), an Oral, RAS(ON) G12D-Selective, Tri-Complex Inhibitor in Patients with KRAS G12D NonSmall Cell Lung Cancer (NSCLC) from a Phase 1 Study in Advanced Solid Tumors

May 23rd, 2025

Asciminib Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase in the Pivotal Phase 3 ASC4FIRST Study: Week 96 Update

May 15th, 2025

Long-Term Safety and Efficacy of Selinexor Maintenance Treatment in Patients With TP53 Wild-Type Advanced or Recurrent Endometrial Cancer: Follow-up Subgroup Analysis of the ENGOT-EN5/GOG-3055/SIENDO Study

April 17th, 2025

Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results From the ACE-536-MF-001 Study

April 16th, 2025

Osimertinib After Definitive Chemoradiotherapy in Patients with Unresectable Stage III EGFRm NSCLC: Updated Overall Survival Analysis From the LAURA Study

April 16th, 2025

Prognostic and Predictive Role of Circulating Tumor DNA (ctDNA) in Stage III Colon Cancer Treated With Celecoxib: Findings from CALGB (Alliance)/SWOG 80702

April 16th, 2025

ctDNA as a Marker of Recurrence Risk in stage III CRC: The α-CORRECT Study

March 13th, 2025

The Effects of Prior Lines of Therapy on Clinical Outcomes for Patients with Chronic Graft-Versus-Host Disease Receiving Axatilimab: A Post Hoc Analysis of Agave-201

March 10th, 2025

The ARANOTE Phase 3 Trial of Darolutamide Plus Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer: Efficacy and Safety by Disease Volume

March 7th, 2025

Safety and Efficacy of BAY 2927088 in Patients with HER2-Mutant NSCLC: Expansion Cohort from the Phase I/II SOHO-01 Study

February 21st, 2025

Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial

February 11th, 2025

First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW

February 6th, 2025

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study

February 3rd, 2025

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

January 30th, 2025

Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)

January 30th, 2025

Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial

January 28th, 2025

Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial

January 22nd, 2025

Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow Up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)

January 17th, 2025

Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

January 14th, 2025

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

January 14th, 2025

Long-term clinical outcomes in patients with Waldenström macroglobulinemia (WM) who received zanubrutinib in the phase 3 ASPEN study: A report from the zanubrutinib extension study

January 14th, 2025

Sonrotoclax and Zanubrutinib as Frontline Treatment for CLL Demonstrates High MRD Clearance Rates with Good Tolerability: Data from an Ongoing Phase 1/1b Study BGB-11417-101

January 14th, 2025

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

January 9th, 2025

Real-World Head-to-Head Analyses Comparing Different Treatment Options For metastatic Castration-Sensitive Prostate Cancer

January 9th, 2025

Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML

January 8th, 2025

Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial

January 6th, 2025

Glofitamab plus Gemcitabine and Oxaliplatin (Glofit-GemOx) for Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL): Results of a Global Randomized Phase III Trial (STARGLO)

December 24th, 2024

Deep and Sustained Responses in Patients With CLL Treated With Zanubrutinib or Zanubrutinib + Obinutuzumab in Phase 1/2 AU-003 and Phase 1b GA-101 Studies: A Report From the Zanubrutinib Extension Study

December 23rd, 2024

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory Waldenström Macroglobulinemia: Results From the Phase 1 CaDAnCe-101 Study

December 23rd, 2024

Ziftomenib Combined with Venetoclax/Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET‑007

December 23rd, 2024

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analyses of Minimal Residual Disease (MRD) Negativity Dynamics in the Phase 3 Imroz Study

December 23rd, 2024

Elacestrant real-world progression-free survival (rwPFS) of adult patients with ER+/HER2-, advanced breast cancer: a retrospective analysis using insurance claims in the United States

December 18th, 2024

Effects of trastuzumab deruxtecan (T-DXd) on health-related quality of life (HRQOL): DESTINY-Breast12 (DB-12) results

December 18th, 2024

Sustained Superiority of Zanubrutinib vs Bendamustine + Rituximab in Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN CLL): 5-Year Follow-Up of Cohort 1 from the SEQUOIA Study

December 18th, 2024

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

December 18th, 2024

Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer

December 17th, 2024

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

December 17th, 2024

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

December 17th, 2024

Cemiplimab Monotherapy for First Line Advanced NSCLC Patients With PD-L1 Expression ≥50%: 5-y Outcomes of EMPOWER-Lung

November 27th, 2024

Trastuzumab Deruxtecan in Patients With HER2+ Advanced/Metastatic Breast Cancer With or Without Brain Metastases: DESTINY-Breast12 Primary Results

November 27th, 2024

Phase 3 MIRASOL Trial: Updated Overall Survival Results of Mirvetuximab Soravtansine (MIRV) Versus Investigator’s Choice (IC) Chemotherapy in Patients (pts) With Platinum-Resistant Ovarian Cancer (PROC) and High Folate Receptor-Alpha (FR⍺) Expression

October 30th, 2024

Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors

October 30th, 2024

Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)

October 18th, 2024

Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera

October 18th, 2024

Five-year Overall Survival (OS) and OS by Tumor Response Measures from the Phase 3 HIMALAYA Study of Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma (uHCC)

October 17th, 2024

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

October 14th, 2024

Subcutaneous Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Therapy in Newly Diagnosed Multiple Myeloma After Transplant: Primary Results from the Phase 3 AURIGA Study

October 10th, 2024

Phase I/II ARROS-1 Study of Zidesamtinib (NVL-520) in ROS1 Fusion-positive Solid Tumours

September 30th, 2024

Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer

September 30th, 2024

Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need

September 27th, 2024

Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial

September 27th, 2024

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors

August 22nd, 2024

Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study

August 6th, 2024

Outcomes of Larotrectinib Compared With Real-World Data From Non-TRK Inhibitor Therapies in Patients With TRK Fusion Cancer: VICTORIA Study

July 30th, 2024

Trastuzumab Deruxtecan in Patients With Metastatic Non-Small-Cell Lung Cancer (DESTINY-Lung01): Primary Results of the HER2 Overexpressing Cohorts From a Single-Arm, Phase 2 Trial

July 30th, 2024

Results From the Phase 1 Study of the Novel BCL2 Inhibitor Sonrotoclax in Combination with Zanubrutinib for Relapsed/Refractory CLL/SLL Show Deep and Durable Responses

July 26th, 2024

Phase 1b Study of Azacitidine, Venetoclax and Revumenib in Newly Diagnosed Older Adults with NPM1 Mutated or KMT2A Rearranged AML: Interim Results of Dose Escalation from the Beat AML Consortium

July 23rd, 2024

Management of Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice: A Focus on Patient Outcomes Post Erythropoietin Stimulating Agent (ESA) Treatment

July 22nd, 2024

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

July 15th, 2024

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study

July 9th, 2024

Results From the Randomized Phase 3 DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

July 9th, 2024

Zanubrutinib vs. Acalabrutinib in B-Cell Malignancies: An Adverse Event-Based Economic Analysis

July 8th, 2024

Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

July 5th, 2024

Efficacy and Safety of Fruquintinib in Patients With Metastatic Colorectal Cancer According to Prior Treatment Sequence in the Refractory Setting: Results From FRESCO and FRESCO-2

July 5th, 2024

DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)

June 28th, 2024

Zanidatamab in Previously-Treated HER2-Positive (HER2+) Biliary Tract Cancer (BTC): Overall Survival (OS) and Longer Follow-up From the Phase 2b HERIZON-BTC-01 Study

June 27th, 2024

Intracranial Efficacy of Datopotamab Deruxtecan in Patients With Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From TROPION-Lung05

June 27th, 2024

Trastuzumab Deruxtecan (T-DXd) vs Physician’s Choice of Chemotherapy (TPC) in Patients (pts) With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low or HER2-Ultralow Metastatic Breast Cancer (mBC) With Prior Endocrine Therapy (ET): Primary Results From DESTINY-Breast06 (DB-06)

June 25th, 2024

Phase 3 Study Results of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) Versus VRd for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma (IMROZ)

June 25th, 2024

Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial

June 25th, 2024

Osimertinib (osi) After Definitive Chemoradiotherapy (CRT) in Patients (pts) With Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA Study

June 24th, 2024

Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 Study

June 24th, 2024

Updated Safety and Efficacy Data From the Phase 3 MANIFEST-2 Study of Pelabresib in Combination With Ruxolitinib for JAK Inhibitor Treatment-Naïve Patients With Myelofibrosis

June 21st, 2024

Amivantamab Plus Lazertinib vs Osimertinib in First-Line EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) With Biomarkers of High-Risk Disease: A Secondary Analysis From the Phase 3 MARIPOSA Study

June 19th, 2024

Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia and the T315I Mutation: 4-Year Results From OPTIC

June 18th, 2024

Nivolumab Plus Relatlimab vs Nivolumab in Previously Untreated Metastatic or Unresectable Melanoma (RELATIVITY-047): Overall Survival and Melanoma-Specific Survival Outcomes at 3 Years

June 17th, 2024

Five-Year Outcomes With First-Line (1L) Nivolumab + Ipilimumab + Chemotherapy (N + I + C) vs C in Patients (pts) With Metastatic NSCLC (mNSCLC) in CheckMate 9LA

June 17th, 2024

Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study

June 17th, 2024

Long-Term Follow up for Adjuvant Dabrafenib Plus Trametinib in Stage III BRAF-Mutated Melanoma: Final Results of the COMBI-AD Study

June 17th, 2024

Phase 3 Study (PIVOTAL) of Neoadjuvant Intralesional Daromun vs. Immediate Surgery in Fully Resectable Melanoma With Regional Skin and/or Nodal Metastases

June 17th, 2024

Comparative Efficacy of Bruton Tyrosine Kinase Inhibitors in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Network Meta-Analysis

June 16th, 2024

Petosemtamab (MCLA-158) With Pembrolizumab as First-line (1L) Treatment of Recurrent/Metastatic (r/m) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 2 Study

June 16th, 2024

A Phase 0/1 ‘Trigger’ Trial of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Patients With EGFR Alterations or Fusions

June 14th, 2024

BDTX-1535 – A MasterKey EGFR Inhibitor Targeting Classical, Non-Classical, and the C797S Resistance Mutation to Address the Evolved Landscape of EGFR Mutant NSCLC

May 31st, 2024

BTK Inhibitors in CLL: Second Generation Drugs and Beyond

May 30th, 2024

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Patients With Poor Prognosis Hepatocellular Carcinoma

May 27th, 2024

ENGOT-EN20/GOG-3083/XPORT-EC-042 – A Phase III, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced, or Recurrent Endometrial Carcinoma: Rationale, Methods, and Trial Design

May 21st, 2024

PAOLA-1: A Review of Progression-Free Survival and 5-Year Follow-up Overall Survival Analysis: Exploratory Post-Hoc Analysis by Clinical Risk of Relapse

April 25th, 2024

Datopotamab Deruxtecan (Dato-DXd) in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) – Nonsquamous (NSQ) Histology in the Phase 3 TROPION-Lung01 Trial

April 9th, 2024

A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2- Positive Metastatic Breast Cancer With Brain Metastases (BMs) from DESTINY-Breast01, -02, and -03

April 2nd, 2024

Overall Survival in Patients With Primary Advanced or Recurrent Endometrial Cancer Treated With Dostarlimab Plus Chemotherapy in Part 1 of the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

March 29th, 2024

Final Overall Survival Data From a Randomized, Open-Label, Phase 2 Study of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Combination With Nab-Paclitaxel in Patients With Recurrent Platinum-Resistant Ovarian Cancer

March 29th, 2024

Safety and Efficacy of Axatilimab in Patients With Chronic Graft-Versus-Host Disease (AGAVE-201)

March 15th, 2024

Cabozantinib plus Atezolizumab in Locally Advanced/Metastatic Adrenocortical Carcinoma: Results From a Multi-Cohort Basket Phase II Trial (CABATEN/GETNE-T1914)

March 11th, 2024

Guideline Updates in Multiple Myeloma

March 8th, 2024

Durvalumab ± Tremelimumab + Chemotherapy in First-Line Metastatic NSCLC: 5-Year Overall Survival Update from the POSEIDON Study

February 26th, 2024

Ibrutinib Combined With Venetoclax in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results From the Randomized Phase 3 SYMPATICO Study

February 20th, 2024

HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

February 5th, 2024

Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW Study

January 31st, 2024

Nivolumab Plus Chemotherapy vs Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophageal Adenocarcinoma: 4-Year Follow-Up of the CheckMate 649 Study

January 30th, 2024

The result of the phase 3 CHECKMATE 901 trial which looked at Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma

January 30th, 2024

Nivolumab Plus Ipilimumab Versus Sunitinib For First-Line Treatment of Advanced Renal Cell Carcinoma: Long-Term Follow-Up Data From the Phase 3 CheckMate 214 Trial

January 30th, 2024

Inavolisib or Placebo in Combination With Palbociclib and Fulvestrant in Patients With PIK3CA Mutated, Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer: Phase III INAVO120 Primary Analysis

January 29th, 2024

Durable Outcomes with Manageable Safety Leading to Prolonged Survival with Tagraxofusp for Treatment-Naive Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Updated Results from a European Named Patient Program

January 29th, 2024

HER2CLIMB-02: Primary Analysis of a Randomized, Double-blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-positive Metastatic Breast Cancer

January 25th, 2024

EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab With Rituximab and Lenalidomide (R2) vs R2 Alone in Patients With Relapsed or Refractory Follicular Lymphoma

January 23rd, 2024

Safety and Clinical Experience of XPO1 Inhibitors in R/R MM Patients

January 19th, 2024

Treatment Strategies in Triple Class Refractory MM Patients

January 19th, 2024

Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence (RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study

January 10th, 2024

Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed and/or Refractory Follicular Lymphoma after ≥2 Prior Therapies: 3-Year Follow-up from a Pivotal Phase II Study

December 22nd, 2023

Real-World (RW) Systemic Treatment Patterns in US Patients (PTS) With Hepatocellular Carcinoma (HCC) 2020–2022

December 22nd, 2023

Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients With Relapsed/Refractory LBCL: Primary Analysis of a Phase Ib/II Study

December 22nd, 2023

Results of the Phase III Randomized IsKia Trial: Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Lenalidomide-Dexamethasone as Pre-Transplant Induction and Post-Transplant Consolidation in Newly Diagnosed Multiple Myeloma Patients

December 21st, 2023

Broad Superiority of Zanubrutinib Over Bendamustine + Rituximab Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without del(17p)

December 21st, 2023

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

December 20th, 2023

Obecabtagene Autoleucel (obe-cel, AUTO1) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Pooled Analysis of the Ongoing FELIX Phase Ib/II Study

December 20th, 2023

Efficacy and Safety of Luspatercept versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naïve Patients with Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Full Analysis of the COMMANDS Trial

December 19th, 2023

Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

December 19th, 2023

Treatment Effectiveness with Venetoclax-Based Therapy after Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study

December 19th, 2023

Role of XPO1 Inhibitors in the Treatment of Relapsed/Refractory Multiple Myeloma

December 19th, 2023

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

December 19th, 2023

Lisocabtagene Maraleucel in R/R MCL: Primary Analysis Results from the MCL Cohort of the Single-Arm, Multicenter, Seamless Design TRANSCEND NHL 001 Study

December 5th, 2023

Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial

December 5th, 2023

Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion–Mutated Advanced NSCLC: Primary Results From PAPILLON, a Randomized Phase 3 Global Study

November 30th, 2023

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

November 28th, 2023

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC

November 17th, 2023

Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

November 17th, 2023

Amivantamab + Lazertinib Versus Osimertinib as 1L Treatment in EGFR-Mutated Advanced NSCLC: Primary Results From MARIPOSA

November 10th, 2023

innovaTV 301/ENGOT-cx12/GOG-3057: A Global, Randomized, Open-Label, Phase 3 Study of Tisotumab Vedotin vs Investigator’s Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer

October 31st, 2023

Dato-DXd vs Docetaxel in Previously Treated Advanced/Metastatic Non–Small Cell Lung Cancer: Results of the Randomized Phase III Study TROPION-Lung01

October 31st, 2023

EV-302/KEYNOTE-A39: Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin in Combination with Pembrolizumab vs Chemotherapy in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma

October 31st, 2023

Randomized Phase 3 Study of First-line Selpercatinib vs Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC: LIBRETTO-431

October 31st, 2023

Amivantamab Plus Chemotherapy (With or Without Lazertinib) vs Chemotherapy in EGFR-mutated, Advanced NSCLC After Progression on Osimertinib

October 31st, 2023

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab ± Olaparib as a First-Line Treatment for Newly Diagnosed Advanced or Recurrent Endometrial Cancer: Results From the Phase III DUO-E/GOG-3041/ENGOT-EN10 Trial

October 31st, 2023

Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy for Patients with Metastatic HR+/HER2– BC: Primary Results from the Randomized Phase III TROPION-Breast01 Trial

October 30th, 2023

BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in Tyrosine Kinase Inhibitor-Naïve ALK-Rearranged Metastatic NSCLC

October 6th, 2023

Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01

October 6th, 2023

Sacituzumab Govitecan + Pembrolizumab in 1L Metastatic Non–Small Cell Lung Cancer: Preliminary Results of the EVOKE-02 Study

October 4th, 2023

Understanding Efficacy, Safety, and PSA Kinetics of Apalutamide Plus ADT in Patients With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

September 29th, 2023

Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axicabtagene Ciloleucel Versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma

September 7th, 2023

FRESCO-2: A Global Phase 3 Multiregional Clinical Trial Evaluating the Efficacy and Safety of Fruquintinib in Patients With Refractory Metastatic Colorectal Cancer

August 29th, 2023

Predictors of Long-term Progression-Free Survival in Niraparib-Treated Patients in the PRIMA/ENGOT-OV16/GOG-3012 Study

August 22nd, 2023

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS G12C–Mutated Non-Small Cell Lung Cancer Who Have Untreated CNS Metastases

August 18th, 2023

Real-World Patient Characteristics and Treatment Patterns Associated With Tucatinib Therapy in Patients With HER2+ Metastatic Breast Cancer

August 4th, 2023

TRANSCEND FL: Phase 2 Study Results of Lisocabtagene Maraleucel in Patients With R/R Follicular Lymphoma

August 1st, 2023

Trifluridine/Tipiracil Plus Bevacizumab for Third-Line Treatment of Refractory Metastatic Colorectal Cancer: The Phase 3 Randomized SUNLIGHT Study

July 25th, 2023

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

July 19th, 2023

Activity, Tolerability and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed or Refractory NPM1-Mutated AML

July 12th, 2023

Ibrutinib-Rituximab and Venetoclax (IRV) Followed by Risk-Stratified R-HyperCVAD/MTX in Young Patients With Untreated Mantle Cell Lymphoma – Phase-II WINDOW-2 Trial

June 30th, 2023

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer: Outcomes by Blinded Independent Central Review of the RUBY trial (ENGOT-EN6-NSGO/GOG3031/RUBY)

June 29th, 2023

ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel Versus Standard-of-Care as First-Line Therapy in Patients With High-Risk Large B-Cell Lymphoma

June 29th, 2023

Lisocabtagene Maraleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Primary Analysis of TRANSCEND CLL 004

June 29th, 2023

Characterization of Mechanisms of Resistance in Previously Treated Chronic Lymphocytic Leukemia From a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib

June 28th, 2023

Outcomes Following Brexucabtagene Autoleucel Administered as an FDA-Approved Therapy for Adults with Relapsed/Refractory B-ALL

June 27th, 2023

A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL

June 26th, 2023

Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE Study

June 26th, 2023

INDIGO: A Phase 3 Global, Randomized, Double-Blinded Study of Vorasidenib vs Placebo in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1/2 Mutation

June 21st, 2023

Ruxolitinib Versus Best Available Therapy for Polycythaemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomised Trial

June 20th, 2023

Efficacy and Safety Results From the COMMANDS Trial: A Phase 3 Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive Transfusion-Dependent Patients With Lower-Risk Myelodysplastic Syndromes

June 16th, 2023

Efficacy of Sacituzumab Govitecan (SG) in Locally Advanced (LA) or Metastatic Urothelial Cancer (mUC) by Trophoblast Cell Surface Antigen 2 (Trop-2) Expression

June 14th, 2023

Spleen Volume Reduction (SVR) Predicts Overall Survival (OS) in Myelofibrosis (MF) Patients on Pacritinib (PAC) but not Best Available Therapy (BAT): PERSIST-2 Landmark OS Analysis

June 14th, 2023

Five-year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory DLBCL: Final Results From the Phase II L-MIND Study

May 25th, 2023

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

May 19th, 2023

First Report of PhALLCON: A Phase 3 Study Comparing Ponatinib vs Imatinib in Newly Diagnosed Ph+ ALL

May 19th, 2023

Phase IB Study of GDC-6036 in Combination with Cetuximab in Patients With Colorectal Cancer (CRC) With KRAS G12C Mutation

April 28th, 2023

A Phase 1 Clinical Trial Evaluating Monotherapy With Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF‑Altered Solid Tumors and NRAS-Mutant Melanoma

April 27th, 2023

Dostarlimab in Combination with Chemotherapy for the Treatment of Primary Advanced or Recurrent Endometrial Cancer: A Placebo-Controlled Randomized Phase 3 Trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)

April 18th, 2023

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th, 2023

Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Risk in the Phase 3 ARASENS Study

March 8th, 2023

Lifileucel TIL Cell Monotherapy in Patients With Advanced Melanoma After Progression on Immune Checkpoint Inhibitors and Targeted Therapy: Pooled Analysis of Consecutive Cohorts (C-144-01 Study)

February 20th, 2023

Nivolumab plus chemotherapy vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma: 3-year follow-up from CheckMate 649

February 10th, 2023

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics: IKEMA Subgroup Analysis

January 25th, 2023

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m Newly Diagnosed AML Treated with IVO + AZA in the AGILE Study

January 12th, 2023

Updated Overall Survival from the Phase 3 TOPAZ-1 Study of Durvalumab or Placebo plus Gemcitabine and Cisplatin in Patients with Advanced Biliary Tract Cancer

January 10th, 2023

Sacituzumab Govitecan vs Treatment of Physician’s Choice: Efficacy by Trop-2 Expression in the TROPiCS-02 Study of Patients with HR+/HER2– Metastatic Breast Cancer

January 10th, 2023

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

January 6th, 2023

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

January 6th, 2023

Zanubrutinib Demonstrates Superior Progression-Free Survival Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Results from Final Analysis of ALPINE Randomized Phase 3 Study

January 5th, 2023

Momelotinib Long-Term Safety: Pooled Data from Three Phase 3 Randomized-Controlled Trials (RCTs)

January 3rd, 2023

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results of the randomized, phase 3 study DESTINY-Breast03

December 22nd, 2022

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

December 22nd, 2022

EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care Endocrine Therapy in Patients With ER+/HER2- Metastatic Breast Cancer: Updated Results by Duration of Prior CDK4/6i in Metastatic Setting

December 22nd, 2022

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents Within the IMerge Phase 2 Study

December 22nd, 2022

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study

December 22nd, 2022

A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia

December 21st, 2022

Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

December 21st, 2022

Pacritinib Is a Potent ACVR1 Inhibitor with Significant Anemia Benefit in Patients with Myelofibrosis

December 21st, 2022

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer

December 20th, 2022

Uproleselan Added to Cladribine Plus Low-Dose Cytarabine (LDAC) In Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

December 19th, 2022

An Economic Evaluation of Cabazitaxel Versus a Second Androgen Receptor‑targeted Agent (ARTA) for Patients with Metastatic Castration‑resistant Prostate Cancer Previously Treated with Docetaxel and an ARTA: the United States Payer Perspective

December 16th, 2022

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

December 14th, 2022

Rate of Atrial Fibrillation in Patients With B-Cell Malignancies Who Undergo Treatment With Zanubrutinib

December 8th, 2022

Real-World Treatment Patterns and Clinical Outcomes in Radioiodine-Refractory Differentiated Thyroid Cancer (RAI-R-DTC) Patients Treated with Lenvatinib Monotherapy

November 30th, 2022

Updated Efficacy and Safety of Larotrectinib in Patients with Advanced Tropomyosin Receptor Kinase (TRK) Fusion Positive Thyroid Carcinoma

November 18th, 2022

Updated Results of APHINITY at 8.4 Years Median Follow Up

November 17th, 2022

Retrospective Analysis of Anemia Benefit of Pacritinib from the PERSIST-2 Trial

October 19th, 2022

Overall Survival Results From the Phase 3 TROPiCS-02 Study of Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With HR+/HER2– Metastatic Breast Cancer

October 18th, 2022

Comparison of Nationally Representative Samples of Rasburicase vs Allopurinol Post-Hyperuricemia Monotherapy in Hematological Malignancies: Significant Reduction in Tumor Lysis Syndrome Mortality with Rasburicase

October 14th, 2022

Tucatinib plus trastuzumab in patients (pts) with HER2-Positive Metastatic Colorectal Cancer (mCRC): Patient Reported Outcomes from MOUNTAINEER

October 5th, 2022

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma: a randomized, phase 3 trial

September 30th, 2022

Primary Results from the Phase 3 Leap-002 Study: Lenvatinib plus Pembrolizumab versus Lenvatinib as First-Line Therapy for Advanced Hepatocellular Carcinoma

September 29th, 2022

Updated Efficacy and Safety of Lenvatinib Plus Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Advanced Endometrial Cancer: Study 309/KEYNOTE-775

September 28th, 2022

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer (HER2+ mCRC): A Systematic Literature Review and Meta-Analysis of Clinical Outcomes

September 23rd, 2022

Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in Metastatic NSCLC

August 29th, 2022

Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Updated Results from a Phase II Study

August 4th, 2022

Primary Analysis of MOUNTAINEER: A Phase 2 Study of Tucatinib and Trastuzumab for HER2-positive mCRC

July 28th, 2022

Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

July 13th, 2022

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer

July 13th, 2022

Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1

July 13th, 2022

Hematologic Improvements With Ivosidenib + Azacitidine Compared to Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia

July 7th, 2022

Updated Progression-Free Survival and Depth of Response in IKEMA, a randomized phase 3 trial of Isatuximab, Carfilzomib and Dexamethasone (Isa-Kd) vs Kd in Relapsed Multiple Myeloma

July 1st, 2022

Subcutaneous Epcoritamab in Patients with Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results from a Phase 2 Study

June 30th, 2022

Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-SIROLIMUS for Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

June 22nd, 2022

Radiation Segmentectomy for Curative Intent of Unresectable HCC (RASER): A Prospective, Single Arm Study

June 17th, 2022

Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid Carcinoma

March 25th, 2022

Long-Term PFS From TIVO-3: Tivozanib (TIVO) Vs Sorafenib (SOR) in Relapsed/Refractory (R/R) Advanced RCC

March 22nd, 2022

Patient-Reported Outcomes and Changes in PSA in Patients With Advanced Prostate Cancer Treated With Apalutamide in the SPARTAN and TITAN Studies

March 15th, 2022

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin plus Inducible T-cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

March 14th, 2022

Safety and Efficacy of Tucatinib–Trastuzumab-Capecitabine Regimen for Treatment of Leptomeningeal Metastasis in HER2+ Breast Cancer: Results from TBCRC049, A Phase 2 Non-Randomized Study

March 11th, 2022

Attainment of Early, Deep Prostate-Specific Antigen Response in mCSPC: A Comparison of Patients Initiated on Apalutamide or Enzalutamide

March 8th, 2022

Rapid Readout: ARASENS: Darolutamide Versus Placebo in Combination With ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

March 7th, 2022

Part 1 Results of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for RRMM

March 7th, 2022

Rapid Readout: Routine Clinical Practice Use of IRd in Patients With Relapsed/Refractory Multiple Myeloma (The INSURE Study)

February 24th, 2022

Rapid Readout: ctDNA Dynamics and Clinical Outcomes in the Adjuvant Management of Colorectal Cancer (GALAXY Study)

February 18th, 2022

Rapid Readout: HSCT With Omidubicel Achieved Robust Immune Reconstitution and Lower Rates of Severe Infection Compared to UCB Transplantation

February 10th, 2022

Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma

February 9th, 2022

Rapid Readout: Phase 1/2 Trial of Subcutaneous Epcoritamab With R-Squared in Patients with Relapsed or Refractory Follicular Lymphoma

February 8th, 2022

Rapid Readout: Post Hoc Analysis of Responses to Ponatinib in patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial

January 28th, 2022

Addition of Isatuximab to RVd as Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma (GMMG-HD7)

January 27th, 2022

Rapid Readout: Community-Based United States MM-6 Study: Updated Efficacy and Safety, and Reasons for Premature Discontinuation

January 21st, 2022

Rapid Readout: Updated Results From CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucal In Patients With Relapsed/Refractory Multiple Myeloma

January 18th, 2022

Rapid Readout: Pirtobrutinib, A Highly Selective, Noncovalent (Reversible) BTK Inhibitor In Previously Treated CLL/SLL: Updated Results From The Phase 1/2 BRUIN Study

January 14th, 2022

Rapid Readout: Phase 3 Trial (EPCORE DLBCL-1) of Epcoritamab Versus Standard of Care in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

January 12th, 2022

Rapid Readout: Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results from the BRUIN Study

December 23rd, 2021

Rapid Readout: ZUMA‑7: Axicabtagene Ciloleucel versus Standard‑of‑Care Therapy in Patients with Relapsed/Refractory Large B‐Cell Lymphoma

December 23rd, 2021

Rapid Readout: AGILE: ivosidenib + azacitidine versus placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia with an IDH1 mutation

December 23rd, 2021

Rapid Readout: Safety and Efficacy of Menin Inhibition in Patients with MLL-Rearranged and NPM1 Mutant Acute Leukemia: SNDX-5613

December 23rd, 2021

Rapid Readout: Safety and Efficacy of CD37-Targeting Naratuximab Emtansine plus Rituximab in Diffuse Large B-Cell Lymphoma and Other Non-Hodgkin’s B-Cell Lymphomas

December 23rd, 2021

Rapid Readouts: Ibrutinib Plus Rituximab and Venetoclax Followed by Risk-Stratified Chemoimmunotherapy in Young Patients With Previously Untreated MCL

December 23rd, 2021

Rapid Readout: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)

December 22nd, 2021

Rapid Readout: A Phase 3 Prospective, Multicenter, Randomized, Open-Label Trial of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

December 21st, 2021

Rapid Readout: Characterization of Bruton Tyrosine Kinase Inhibitor (BTKi)-Related Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

December 21st, 2021

Rapid Readout: Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2+ Metastatic Breast Cancer: DESTINY-Breast03

December 21st, 2021

Rapid Readouts: Interim Analysis Results From the Phase 2 PRIMO Trial in R/R Peripheral T-Cell Lymphoma

December 20th, 2021

Rapid Readouts: Safety, Tolerability, and Efficacy of Axatilimab, a CSF-1R humanized antibody, for Chronic Graft-versus-Host Disease after 2 or more Lines of Systemic Treatment

December 17th, 2021

Rapid Readouts: 3-Year Overall Survival Update From the Phase 3 CASPIAN Study

November 9th, 2021

Rapid Readouts: Larotrectinib Prior Therapy and Performance Status Outcomes in Patients With Non-CNS TRK Fusion Cancer

November 1st, 2021

Rapid Readouts: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer

November 1st, 2021

T-DXd Versus T-DM1 in HER2+ MBC: Results of DESTINY-Breast03

October 28th, 2021

Rapid Readout: T-DXd in Patients With HER2+ Unresectable or Metastatic Gastric or GEJ Following a Trastuzumab-Containing Regimen

October 27th, 2021

Rapid Readouts: Phase 1 Cohort of TRANSCEND-CLL-004 Study

October 21st, 2021

Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial

October 15th, 2021

ARCHES Final OS Analysis in mHSPC

October 15th, 2021

Rapid Readouts: ODENZA trial

October 7th, 2021

Rapid Readouts: IKEMA Subgroup Analysis in Relapsed Multiple Myeloma Patients With High-Risk Cytogenetics

September 24th, 2021

Rapid Readout: Assessment of Tucatinib vs Placebo in the HER2CLIMB Study of Pretreated Patients with HER2+ Metastatic Breast Cancer

September 9th, 2021

Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer

August 11th, 2021

Rapid Readouts: Results from the Phase 3 VISION Study

August 11th, 2021

Rapid Readouts: First interim analysis of the ALPINE study: a phase III randomized trial of zanubrutinib vs. ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma

July 14th, 2021

Rapid Readouts: Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicentre, open-label phase 2 trial

July 14th, 2021

Rapid Readouts: Safety and Efficacy of Pralsetinib in Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer: Update from the ARROW trial

July 13th, 2021

Rapid Readouts: Updated Results From the Phase 3 SIMPLIFY-1 Trial

July 8th, 2021

Rapid Readouts: SIMPLIFY-1 and SIMPLIFY-2 Trials

July 8th, 2021

Rapid Readouts: Final Analysis of Phase 3 TITAN Trial

July 6th, 2021

Rapid Readouts: Results of the SCOUT and NAVIGATE Trials

July 1st, 2021

Rapid Readouts: Results from two trials of TRK inhibitor, larotrectinib, in patients with TRK fusion-positive lung cancer

July 1st, 2021

Rapid Readouts: Updated data from a pooled analysis of larotrectinib in TRK fusion-positive cancers

July 1st, 2021

Rapid Readouts: Extended Follow-up From the Phase 3 ARAMIS trial

June 30th, 2021

Rapid Readouts: Treatment Preference Results From the Phase 2 ODENZA Trial

June 30th, 2021

Rapid Readouts: Final Results from Phase 3 ClarIDHy Trial

June 24th, 2021

Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial

June 18th, 2021

Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial

June 18th, 2021

Rapid Readouts: A Global Study of Advanced Dosimetry in the Treatment of HCC With Y 90 Glass Microspheres

May 12th, 2021

Rapid Readouts: Results from the Phase 3 CHRONOS-3 Trial for Relapsed iNHL

May 7th, 2021

Rapid Readouts: Phase 2 Trial of Pevonedistat Plus Azacitidine Versus Azacitidine in Higher-Risk MDS/CMML or LB AML

April 28th, 2021

Rapid Readouts: Phase 2 CodeBreak 100 Trial

March 4th, 2021

Rapid Readouts: Final Analysis Results From the Phase 3 TITAN Study

March 3rd, 2021

Rapid Readouts: Postoperative Chemotherapy Use and Outcomes from ADAURA

February 19th, 2021

Rapid Readouts: Patient-Reported Outcomes from ADAURA

February 19th, 2021

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

January 28th, 2021

Rapid Readouts: Phase 2 JULIET Trial

January 26th, 2021

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

January 19th, 2021

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

January 18th, 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

January 18th, 2021

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

January 15th, 2021

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

January 14th, 2021

Rapid Readouts: Five-Year Analysis of MURANO Study

December 23rd, 2020

Rapid Readouts: Updated Results From KX-ORAX-001 Study

December 23rd, 2020

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

December 23rd, 2020

Rapid Readouts: Updated Results From DESTINY-Breast01

December 23rd, 2020

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

December 10th, 2020

Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2

December 10th, 2020

Rapid Readouts: Phase 3 VIALE-A Study

December 3rd, 2020

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

November 18th, 2020

Rapids Readouts: Phase 3 CheckMate 238 Trial

October 30th, 2020

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

October 14th, 2020

Rapid Readouts: Phase 3 HERO Trial

October 8th, 2020

Rapid Readouts: Phase 3 CheckMate 9ER Trial

October 7th, 2020

Rapid Readouts: Phase 3 ASCENT Study

October 5th, 2020

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

August 24th, 2020

Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

July 17th, 2020

Rapid Readouts: Initial Results of the Phase III BOSTON Study

June 29th, 2020

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

June 25th, 2020

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

June 23rd, 2020

Rapid Readouts: Final Analysis of KEYNOTE-189

June 23rd, 2020

Rapid Readouts: Update of CARTITUDE-1

June 23rd, 2020

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

June 19th, 2020

Rapid Readouts: CheckMate 9LA

June 16th, 2020

Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis

June 16th, 2020